Patents by Inventor Toshimasa Yamauchi
Toshimasa Yamauchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170298051Abstract: An AdipoR activator for activating both AdipoR1 and AdipoR2 is provided. A compound represented by the following formula (1), wherein A is a substituted or unsubstituted aryl group or the like, Y1 is (CHR2)a— or the like, X is CH or N, R1 is a C1-7 alkyl group, m is an integer of 0-4, Y2 is *—O—CH2—CONH—, *—CONH—(CH2)b—CO— or the like, Z is a cyclic group, B may be a substituent of the cyclic group represented by Z, and n is an integer of 0-3.Type: ApplicationFiled: April 28, 2017Publication date: October 19, 2017Applicants: THE UNIVERSITY OF TOKYO, RIKENInventors: Takashi KADOWAKI, Toshimasa Yamauchi, Miki Iwabu, Masato Iwabu, Shigeyuki Yokoyama, Teruki Honma
-
Publication number: 20160214967Abstract: An AdipoR activator for activating both AdipoR1 and AdipoR2 is provided. A compound represented by the following formula (1), wherein A is a substituted or unsubstituted aryl group or the like, Y1 is (CHR2)a— or the like, X is CH or N, R1 is a C1-7 alkyl group, m is an integer of 0-4, Y2 is *—O—CH2—CONH—, *—CONH—(CH2)b—CO— or the like, Z is a cyclic group, B may be a substituent of the cyclic group represented by Z, and n is an integer of 0-3.Type: ApplicationFiled: September 30, 2014Publication date: July 28, 2016Applicants: THE UNIVERSITY OF TOKYO, RIKENInventors: Takashi KADOWAKI, Toshimasa YAMAUCHI, Miki IWABU, Masato IWABU, Shigeyuki YOKOYAMA, Teruki HONMA
-
Publication number: 20130274185Abstract: A pharmaceutical for pseudo-exercise therapy containing an adiponectin receptor 1 agonist compound as an active ingredient and changing the physiological state of muscle to a post-exercise one without applying an exercise stress to the muscle.Type: ApplicationFiled: March 15, 2011Publication date: October 17, 2013Applicant: THE UNIVERSITY OF TOKYOInventors: Takashi Kadowaki, Toshimasa Yamauchi, Masato Iwabu, Miki Iwabu
-
Publication number: 20130273567Abstract: A method of screening for candidate compounds for adiponectin receptor 1 agonist including a step of bringing test compounds into contact with cells to determine whether they cause intracellular influx of extracellular calcium ions and selecting, from the test compounds, compounds causing the intracellular influx of extracellular calcium ions as the candidate compounds for adiponectin receptor 1 agonist.Type: ApplicationFiled: March 15, 2011Publication date: October 17, 2013Inventors: Takashi Kadowaki, Toshimasa Yamauchi, Masato Iwabu, Miki Iwabu, Kazushige Touhara
-
Publication number: 20130236893Abstract: A single-nucleotide polymorphism in the UBE2E2 locus or C2CD4A-C2CD4B locus is analyzed and type II diabetes is examined based on the results of the analysis.Type: ApplicationFiled: September 2, 2011Publication date: September 12, 2013Applicants: TOKUSHUKAI, RIKENInventors: Shiro Maeda, Takashi Kadowaki, Toshimasa Yamauchi, Kazuo Hara
-
Patent number: 8252584Abstract: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.Type: GrantFiled: June 3, 2011Date of Patent: August 28, 2012Assignees: Toudai TLO, Ltd., Nissan Chemical Industries, Ltd.Inventors: Takashi Kadowaki, Toshimasa Yamauchi, Ryozo Nagai, Junji Kamon
-
Publication number: 20120027760Abstract: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.Type: ApplicationFiled: June 3, 2011Publication date: February 2, 2012Applicants: Nissan Chemical Industries, Ltd., TOUDAI TLO, Ltd.Inventors: Takashi KADOWAKI, Toshimasa Yamauchi, Ryozo Nagai, Junji Kamon
-
Patent number: 8039223Abstract: Kits and methods for selectively assaying a target adiponectin multimer in a biological sample. Such methods accurately evaluate the relationship between a disease and adiponectin through selective assay of adiponectin multimers and provide information that cannot be obtained through measurement of the total amount of adiponectin alone. A method for selectively assaying a target adiponectin multimer in a biological sample comprising distinguishing target adiponectin multimer from the other adiponectin multimers by using a protease and/or an antibody.Type: GrantFiled: May 19, 2009Date of Patent: October 18, 2011Assignees: Sekisui Medical Co., Ltd., Toudai TLO, Ltd.Inventors: Hiroyuki Ebinuma, Hirokazu Yago, Yuka Akimoto, Osamu Miyazaki, Takashi Kadowaki, Toshimasa Yamauchi, Kazuo Hara
-
Patent number: 7977459Abstract: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.Type: GrantFiled: January 29, 2009Date of Patent: July 12, 2011Assignees: TOUDAI TLO, Ltd., Nissan Chemical Industries, Ltd.Inventors: Takashi Kadowaki, Toshimasa Yamauchi, Ryozo Nagai, Junji Kamon
-
Publication number: 20110065780Abstract: The invention provides an insulin resistance improving agent and a therapeutic agent for type 2 diabetes, which contain a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a method for improving insulin resistance and treating type 2 diabetes by administering the aforementioned agent(s).Type: ApplicationFiled: October 18, 2010Publication date: March 17, 2011Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Takashi KADOWAKI, Toshimasa Yamauchi, Junji Kamon, Hironori Waki, Ryozo Nagai, Satoshi Kimura, Motoo Tomita
-
Patent number: 7850976Abstract: The invention provides an insulin resistance improving agent and a therapeutic agent for type 2 diabetes, which contain a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a method for improving insulin resistance and treating type 2 diabetes by administering the aforementioned agent(s).Type: GrantFiled: March 3, 2008Date of Patent: December 14, 2010Assignee: Japan Science and Technology AgencyInventors: Takashi Kadowaki, Toshimasa Yamauchi, Junji Kamon, Hironori Waki, Ryozo Nagai, Satoshi Kimura, Motoo Tomita
-
Publication number: 20100303855Abstract: A substance preventing adverse actions of conventional fibrate-series drugs as therapeutic agents for the metabolic syndrome and dyslipidemia to enhance the therapeutic effects thereof comprises an extract from Dunaliella salina or Dunaliella bardawil, for administration in combination with the fibrate-series drugs. The substance suppresses liver hypertrophy caused by the fibrate-series drugs as PPAR-? agonists and has an action of promoting fat combustion, suppressing fat synthesis and suppressing cell proliferation, to prevent disorders of liver functions.Type: ApplicationFiled: August 9, 2010Publication date: December 2, 2010Inventors: Takashi Kadowaki, Toshimasa Yamauchi, Nobuo Mori, Osamu Sueno, Sachiko Kawamoto
-
Publication number: 20100273708Abstract: The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic diseases, as well as methods of searching for adiponectin expression-inducing agents. KLF9, which can bind to the 32-bp fragment of position ?188 to position ?157 from the adiponectin expression start site, was demonstrated to enhance adiponectin promoter activity. Therefore, the present invention uses KLF9 as an adiponectin expression-inducing agent, and suggests that KLF9 replenishment therapy is useful for preventing and/or treating obesity or obesity-related diseases including metabolic diseases such as insulin resistance and type II diabetes, and cardiovascular diseases.Type: ApplicationFiled: April 19, 2010Publication date: October 28, 2010Applicants: TOUDAI TLO, Ltd., NISSAN CHEMICAL INDUSTRIES, LTD.Inventors: Takashi KADOWAKI, Toshimasa Yamauchi, Shoko Kitajima, Yusuke Ito
-
Patent number: 7781171Abstract: The invention provides a method of pretreating a sample for conveniently, quickly and accurately measuring the total amount of adiponectin present in a biological sample contaminated with various adiponectin multimers. The method of measuring an sample for immunologically assaying the total amount of adiponectin present in the sample comprises reacting, with an adiponectin-containing sample, at least one of a reducing agent, an acid or a salt thereof, a surfactant, and a protease.Type: GrantFiled: October 15, 2004Date of Patent: August 24, 2010Assignees: Daiichi Pure Chemicals Co., Ltd., Toudai TLO, Ltd.Inventors: Hiroyuki Ebinuma, Hirokazu Yago, Yuka Akimoto, Osamu Miyazaki, Takashi Kadowaki, Toshimasa Yamauchi
-
Patent number: 7741080Abstract: The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic diseases, as well as methods of searching for adiponectin expression-inducing agents. KLF9, which can bind to the 32-bp fragment of position ?188 to position ?157 from the adiponectin expression start site, was demonstrated to enhance adiponectin promoter activity. Therefore, the present invention uses KLF9 as an adiponectin expression-inducing agent, and suggests that KLF9 replenishment therapy is useful for preventing and/or treating obesity or obesity-related diseases including metabolic diseases such as insulin resistance and type II diabetes, and cardiovascular diseases.Type: GrantFiled: March 31, 2005Date of Patent: June 22, 2010Assignees: Nissan Chemical Industries, Ltd., Toudai TLO, LtdInventors: Takashi Kadowaki, Toshimasa Yamauchi, Shoko Kitajima, Yusuke Ito
-
Publication number: 20100120674Abstract: The invention provides an insulin resistance improving agent and a therapeutic agent for type 2 diabetes, which contain a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a method for improving insulin resistance and treating type 2 diabetes by administering the aforementioned agent(s).Type: ApplicationFiled: March 3, 2008Publication date: May 13, 2010Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: TAKASHI KADOWAKI, TOSHIMASA YAMAUCHI, JUNJI KAMON, HIRONORI WAKI, RYOZO NAGAI, SATOSHI KIMURA, MOTOO TOMITA
-
Publication number: 20100098720Abstract: A substance preventing adverse actions of conventional fibrate-series drugs as therapeutic agents for the metabolic syndrome and dyslipidemia to enhance the therapeutic effects thereof comprises an extract from Dunaliella salina or Dunaliella bardawil, for administration in combination with the fibrate-series drugs. The substance suppresses liver hypertrophy caused by the fibrate-series drugs as PPAR-? agonists and has an action of promoting fat combustion, suppressing fat synthesis and suppressing cell proliferation, to prevent disorders of liver functions.Type: ApplicationFiled: April 24, 2009Publication date: April 22, 2010Inventors: Takashi Kadowaki, Toshimasa Yamauchi, Nobuo Mori, Osamu Sueno, Sachiko Kawamoto
-
Publication number: 20100062541Abstract: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.Type: ApplicationFiled: January 29, 2009Publication date: March 11, 2010Applicants: TOUDAI TLO, Ltd., Nissan Chemical Industries, Ltd.Inventors: Takashi Kadowaki, Toshimasa Yamauchi, Ryozo Nagai, Junji Kamon
-
Publication number: 20090291461Abstract: Kits and methods for selectively assaying a target adiponectin multimer in a biological sample. Such methods accurately evaluate the relationship between a disease and adiponectin through selective assay of adiponectin multimers and provide information that cannot be obtained through measurement of the total amount of adiponectin alone. A method for selectively assaying a target adiponectin multimer in a biological sample comprising distinguishing target adiponectin multimer from the other adiponectin multimers by using a protease and/or an antibody.Type: ApplicationFiled: May 19, 2009Publication date: November 26, 2009Applicants: DAIICHI PURE CHEMICALS CO., LTD, TOUDAI TLO, LTD.Inventors: Hiroyuki EBINUMA, Hirokazu Yago, Yuka Akimoto, Osamu Miyazaki, Takashi Kadowaki, Toshimasa Yamauchi, Kazuo Hara
-
Patent number: 7608405Abstract: Methods for selectively assaying a target adiponectin multimer in a biological sample. Such methods accurately evaluate the relationship between a disease and adiponectin through selective assay of adiponectin multimers and provide information that cannot be obtained through measurement of the total amount of adiponectin alone. A method for selectively assaying of a target adiponectin multimer in a biological sample comprising distinguishing target adiponectin multimer from the other adiponectin multimers by using a protease and/or an antibody.Type: GrantFiled: October 15, 2004Date of Patent: October 27, 2009Assignees: Daiichi Pure Chemicals Co., Ltd., Toudai TLO, Ltd.Inventors: Hiroyuki Ebinuma, Hirokazu Yago, Yuka Akimoto, Osamu Miyazaki, Takashi Kadowaki, Toshimasa Yamauchi, Kazuo Hara